Skip to main content

Home/ Dr. Goodyear/ Group items tagged immunotherapy

Rss Feed Group items tagged

Filter: All | Bookmarks | Topics Simple Middle
Nathan Goodyear

1a,25-Dihydroxyvitamin D3 as New Immunotherapy in Treatment of Recurrent Spontaneous Ab... - 0 views

www.scribd.com/...urrent-Spontaneous-AbortionOri

vitamind D inflammation INF-gamma TNF-alpha IL-2

shared by Nathan Goodyear on 24 Sep 11 - No Cached
  • Nathan Goodyear on 24 Sep 11
     
    Vitamin D lowers INF-gamma, TNF-alpha, and IL-2 cytokines.  Vitamin D reduces inflammation.
Nathan Goodyear

Safety and immunologic effects of high- vs low-dose cholecalciferol in multiple sclerosis - 0 views

www.neurology.org/...WNL.0000000000002316

multiple Sclerosis MS vitamin D inflammation IL-17

shared by Nathan Goodyear on 07 Jan 16 - No Cached
  • Nathan Goodyear on 07 Jan 16
     
    Not only is high dose vitamin D3 therapy more effective in reducing IL-17 compared to low dose, but it is safe to in individuals with MS.  The hot topic these days is immunotherapy: that is exactly what vitamin D therapy is.
Nathan Goodyear

The advent of oncolytic virotherapy in oncology: The Rigvir® story. - PubMed... - 0 views

www.ncbi.nlm.nih.gov/...30179611

RIGVIR cancer immunotherapy immunotherapy cancer

shared by Nathan Goodyear on 19 Oct 18 - No Cached
  • Nathan Goodyear on 19 Oct 18
     
    The RIGVIR story; only abstract available here.
Nathan Goodyear

Long-term treatment with the oncolytic ECHO-7 virus Rigvir of a melanoma stage IV M1c p... - 0 views

www.ncbi.nlm.nih.gov/...27457663

Cancer RIGVIR immunotherapy immunotherapy cancer

shared by Nathan Goodyear on 19 Oct 18 - No Cached
  • Nathan Goodyear on 19 Oct 18
     
    3 cases reports of the use of the oncolytic RIGVIR virus in stage III and stage IV disease.
Nathan Goodyear

Effect of the oncolytic ECHO-7 virus Rigvir® on the viability of cell lines o... - 0 views

www.ncbi.nlm.nih.gov/...PMC5868171

RIGVIR cancer immunotherapy immunotherapy cancer

shared by Nathan Goodyear on 19 Oct 18 - No Cached
  • Nathan Goodyear on 19 Oct 18
     
    In vitro studies confirm reduced viability of melanoma, rhabdomyoscarcoma, gastric adenocarcinoma, lun carcinoma, and pancreas adenocarcinoma cells with the use of the oncolytic RIGVIR virus
Nathan Goodyear

Efficacy of the concomitant administration of the pineal hormone melatonin in cancer im... - 0 views

www.ncbi.nlm.nih.gov/...8208518

IL-2 melatonin cancer immunotherapy

shared by Nathan Goodyear on 01 Jun 18 - No Cached
  • Nathan Goodyear on 01 Jun 18
     
    melatonin found to enhance the IL-2 anti-tumor activity in preliminary study.
Nathan Goodyear

PayPerView: A Randomized Study of Low-Dose Subcutaneous lnterleukin-2 Plus Melatonin ve... - 0 views

www.karger.com/...227465

IL-2 cancer melatonin colon cancer colorectal cancer

shared by Nathan Goodyear on 09 Nov 18 - No Cached
  • Nathan Goodyear on 09 Nov 18
     
    Percent survival at 1 year was significantly increased in patients treated with immunotherapy than in those treated with supportive care alone (9/25 vs. 3/25, p < 0.05) in study which suggests that low-dose subcutaneous IL-2 plus melatonin may be effective as a second-line therapy to induce tumor regression and to prolong percent survival at 1 year in metastatic colorectal cancer patients progressing under 5-FU and folates
Nathan Goodyear

Efficacy of Melatonin in the Immunotherapy of Cancer Using lnterleukin-2 | SpringerLink - 0 views

link.springer.com/...978-3-642-59512-7_26

cancer IL-2 melatonin immunotherapy

shared by Nathan Goodyear on 09 Nov 18 - No Cached
  • Nathan Goodyear on 09 Nov 18
     
    Low dose IL-2 + high dose melatonin increases 1 year survival in the treatment of solid tumors in pilot study.
Nathan Goodyear

Re-emergence of dendritic cell vaccines for cancer treatment - 0 views

www.cell.com/...S2405-8033(17)30240-6

"Dendritic cell vaccine" dendritic cells

shared by Nathan Goodyear on 24 Oct 18 - No Cached
  • Nathan Goodyear on 24 Oct 18
     
    Great, updated review on the future of immunotherapy, here and now.
Nathan Goodyear

Tumor-infiltrating lymphocytes in melanoma - 0 views

www.ncbi.nlm.nih.gov/...PMC3462483

Melanoma TIL "tumor-infiltrating lymphocytes"

shared by Nathan Goodyear on 16 Nov 18 - No Cached
  • Nathan Goodyear on 16 Nov 18
     
    TIL immunotherapy in the treatment of melanoma
Nathan Goodyear

Evolving landscape of human epidermal growth factor receptor 2-positive breast cancer t... - 0 views

www.sciencedirect.com/...S0960977617300103

HER-2 breast cancer cancer herceptin Perjeta

shared by Nathan Goodyear on 06 Aug 18 - No Cached
  • 15%–20%
  • key mediator of cell growth, differentiation, and survival
  • of higher histological grade and are more likely to invade axillary lymph nodes
  • ...15 more annotations...
  • shortened survival and an increased risk of disease recurrence and metastasis
  • Currently, four HER2-directed agents are approved for the treatment of patients with HER2+ breast cancer: trastuzumab, pertuzumab, lapatinib, and ado-trastuzumab emtansine (T-DM1)
  • biosimilars
  • trastuzumab may provide greater benefit when administered concurrently with chemotherapy rather than after, and this has become the standard approach
  • concurrent use of anthracyclines (ie, doxorubicin or epirubicin) and trastuzumab is not recommended because of an increased risk for cardiac toxicity
    • Nathan Goodyear
      Nathan Goodyear on 06 Aug 18
       
      avoid herceptin in conjuction with antracyclines i.e. doxorubicin
  • Sequential doxorubicin plus cyclophosphamide followed by concomitant paclitaxel or docetaxel and trastuzumab is recommended for most patients
    • Nathan Goodyear
      Nathan Goodyear on 06 Aug 18
       
      top recommended regimen combination
  • Guidelines also recommend trastuzumab in combination with paclitaxel, docetaxel and carboplatin, or docetaxel and cyclophosphamide, particularly for patients with increased risk for cardiac toxicity or those with small (≤1&nbsp;cm), node-negative HER2+ tumors
    • Nathan Goodyear
      Nathan Goodyear on 06 Aug 18
       
      good alternative in patients with increased risk of cardiac toxicity.
  • guidelines recommend up to 1 year of adjuvant trastuzumab
  • Neoadjuvant chemotherapy with trastuzumab is associated with higher rates of pathologic complete response (pCR) than chemotherapy alone or in combination with lapatinib
  • the combination of trastuzumab, lapatinib, and chemotherapy is not recommended because it failed to demonstrate noninferiority versus trastuzumab and chemotherapy in the adjuvant setting
  • recommend the combination of trastuzumab, pertuzumab, and chemotherapy as neoadjuvant treatment for patients with locally advanced HER2+ breast cancer and for some patients (node-positive or tumor ≥2&nbsp;cm) with early-stage disease
  • neoadjuvant chemotherapy in combination with pertuzumab and trastuzumab reduced the risk of progression or death by 31% and recurrence or death by 40% versus trastuzumab alone
  • Concurrent chemotherapy and HER2-directed therapy improves survival outcomes over chemotherapy alon
  • dual inhibition of HER2 with trastuzumab and pertuzumab in combination with paclitaxel reduced the risk of death or progression by approximately 40% compared with concurrent trastuzumab and paclitaxel
  • the combination of trastuzumab, pertuzumab, and taxane chemotherapy is the preferred first-line regimen
  • Nathan Goodyear on 06 Aug 18
     
    HER-2 + breast cancer = appx 15-20% of all breast cancers and is a marker of worse prognosis and an indication for targeted immunotherapy blockade.
Nathan Goodyear

Immunotherapy for Prostate Cancer with Gc Protein-Derived Macrophage-Activating Factor,... - 0 views

europepmc.org/...PMC2510818

GC-MAF Nagalase cancer prostate cancer immunotherapy PSA

shared by Nathan Goodyear on 08 May 18 - No Cached
  • the MAF precursor activity of prostate cancer patient Gc protein is lost or reduced, because their serum Gc protein is deglycosylated by serum α-N-acetylgalactosaminidase (Nagalase) secreted from cancerous cells
  • Administration of 100 ng of GcMAF
  • 100 ng of GcMAF was administered intramuscularly once a week
  • ...11 more annotations...
  • As GcMAF therapy progressed the MAF precursor activity of all five patients increased and their serum Nagalase activity decreased inversely
  • As GcMAF therapy progressed, the MAF precursor activity increased with a concomitant decrease in serum Nagalase activity
  • serum Nagalase is proportional to tumor burden
  • as GcMAF therapy progressed, serum Nagalase activity decreased and, concomitantly, tumor burden decreased
  • the serum Nagalase activities of all 16 patients decreased as GcMAF therapy progressed
  • annual computed tomographic scans of these patients confirmed them being tumor recurrence-free for the 7 years
  • undifferentiated cells were killed rapidly during the first few weeks, and the differentiated cells were killed slowly in the remaining GcMAF therapeutic period
  • PSA levels of prostatectomized patients decreased as serum Nagalase decreased during GcMAF therapy
  • In patients without tumor resection, however, although serum Nagalase activity decreased as GcMAF therapy progressed, their PSA values remained unchanged. The result suggests that the PSA derived from tumor-bearing prostate did not change while tumor burden decreased. Because tumor-induced inflammation in the noncancerous prostate tissues causes secretion of PSA [38], the PSA produced from these inflamed noncancerous prostate tissues cannot be changed by the decrease in tumor burden
  • Advanced cancer patients have high serum Nagalase activities, resulting in no macrophage activation and severe immunosuppression that explain why cancer patients die with overwhelming infection
  • Prognostic utility of serum α-N-acetylgalactosaminidase and immunosuppression resulted from deglycosylation of serum Gc protein in oral cancer patients
  • Nathan Goodyear on 08 May 18
     
    GC-MAF levels exist in inverse relationship to nagalase.  In this study of men with prostate cancer, weekly GCMAF injections reduced Nagalase activity to levels found in healthy controls suggesting tumor free. The dose was 100 ng/week. Nagalase is a protein that suppresses GC-MAF production and thus is immunosuppressive.
Nathan Goodyear

Promising role for Gc-MAF in cancer immunotherapy: from bench to bedside - 0 views

www.ncbi.nlm.nih.gov/...PMC5686300

nagalase Gc-MAF cancer

shared by Nathan Goodyear on 29 Jan 18 - No Cached
  • MAF precursor activity has also been lost or reduced after Gc-globulin treatment in some cancer cell lines
  • This appears to result from the deglycosylated ɑ-N-acetylgalactosaminidase (nagalase) secreted from cancerous cells
  • Nagalase has been detected in many cancer patients, but not in healthy individuals
  • ...31 more annotations...
  • Studies have shown that the production of nagalase has a mutual relationship with Gc-MAF level and immunosuppression
  • It has been demonstrated that serum levels of nagalase are good prognosticators of some types of cancer
  • The nagalase level in serum correlates with tumor burden and it has been shown that Gc-MAF therapy progresses, nagalase activity decreases
  • It has been shown that Gc-MAF can inhibit the angiogenesis induced by pro-inflammatory prostaglandin E1
  • The effect of Gc-MAF on chemotaxis or activation of tumoricidal macrophages is likely the main mechanism against angiogenesis.
  • Administration of Gc-MAF stimulates immune-cell progenitors for extensive mitogenesis, activates macrophages and produces antibodies. “This indicates that Gc-MAF is a powerful adjuvant for immunization.”
  • Cancer cell lines do not develop into tumor genes in mouse models after Gc-MAF-primed immunization (29-31) and the effect of Gc-MAF has been approved for macrophage stimulation for angiogenesis, proliferation, migration and metastatic inhibition on tumors induced by MCF-7 human breast cancer cell line
  • The protocol included: "a high dose of second-generation Gc-MAF (0.5 ml) administered twice a week intramuscularly for a total of 21 injections.”
  • Yamamoto et al. showed that the administration of Gc-MAF to 16 patients with prostate cancer led to improvements in all patients without recurrence
  • Inui et al. reported that a 74-year-old man diagnosed with prostate cancer with multiple bone metastases was in complete remission nine months after initiation of GcMAF therapy simultaneously with hyper T/NK cell, high-dose vitamin C and alpha lipoic acid therapy
  • It has also been approved for non-neoplastic diseases such as autism (41), multiple sclerosis (42, 43), chronic fatigue syndrome (CFS) (40), juvenile osteoporosis (44) and systemic lupus erythematous (45).
  • Gc-MAF has been verified for use in colon, thyroid (38), lung (39), liver, thymus (36), pancreatic (40), bladder and ovarian cancer and tongue squamous carcinoma
  • Prostate, breast, colon, liver, stomach, lung (including mesothelioma), kidney, bladder, uterus, ovarian, head/neck and brain cancers, fibrosarcomas and melanomas are the types of cancer tested thus far
  • weekly administration of 100 ng Gc-MAF to cancer at different stages and types showed curative effects at different follow-up times
  • this treatment has been suggested for non-anemic patients
  • Studies have shown that weekly administration of 100 ng Gc-MAF to cancer patients had curative effects on a variety of cancers
  • Because the half-life of the activated macrophages is approximately one week, it must be administered weekly
  • In vivo weekly intramuscular administration of Gc-MAF (100 ng) for 16-22 weeks was used to treat patients with breast cancer
  • individuals harboring different VDR genotypes had different responses to Gc-MAF and that some genotypes were more responsive than others
  • Administration of Gc-MAF for cancer patients exclusively activates macrophages as an important cell in adaptive immunity
  • Gc-MAF supports humoral immunity by producing, developing and releasing large quantities of antibodies against cancer. Clinical evidence from a human model of breast cancer patients supports this hypothesis
  • There is also evidence that confirms the tumoricidal role of Gc-MAF via Fc-receptor mediation
  • It is likely that the best therapeutic responses will be observed when the nutritional and inflammatory aspects are taken together with stimulation of the immune system
  • it should be noted that no harmful side effects of Gc-MAF treatment have been reported, even when it was successfully administered to autistic children
  • The natural activation mechanism of macrophages by Gc-MAF is so natural and it should not have any side effects on humans or animal models even in cell culture
  • Besides the Gc-MAF efficacy on macrophage activity, it can be a potential anti-angiogenic agent (28) and an inhibitor of the migration of cancerous cells in the absence of macrophages (47).
  • Activating or modifying natural killer cells, dendritic cells, DC, CTL, INF and IL-2 have all been recommended for cancer immunotherapy
  • It has been reported that nagalase cannot deglycosylate Gc-MAF as it has specificity for Gc globulin alone
  • inflammation-derived macrophage activation with the participation of B and T lymphocytes is the main mechanism
  • macrophages highly-activated by the addition of Gc-MAF can show tumoricidal activity
  • Previous clinical investigations have confirmed the efficacy of Gc-MAF. In addition to activating existing macrophages, Gc-MAF is a potent mitogenic factor that can stimulate the myeloid progenitor cells to increase systemic macrophage cell counts by 40-fold in four days
  • Nathan Goodyear on 29 Jan 18
     
    great review on Gc-MAF in cancer.  An increase in nagalase blocks Gc-protein to Gc-MAF activity leaving the host immune system compromised.
Nathan Goodyear

Immunotherapy with subcutaneous low dose interleukin-2 plus melatonin as salvage therap... - 0 views

www.spandidos-publications.com/...947

cancer IL-2 immunotherapy melatonin ovarian cancer

shared by Nathan Goodyear on 10 May 18 - No Cached
  • Nathan Goodyear on 10 May 18
     
    Small phase II pilot sutyd of advanced ovarian cancer, foud low dose IL-2 at 3 million IU/day X 6 days for 4 weeks preceded by 40 mg melatonin provides some benefit in advanced disease following at least 3 failed polychemotherapy regimens.  
Nathan Goodyear

Histamine: A Novel Approach to Cancer Immunotherapy: Cancer Investigation: Vol 18, No 4 - 0 views

www.tandfonline.com/...07357900009012178

histamine NK IL-2 cancer immunotherapy

shared by Nathan Goodyear on 12 May 18 - No Cached
  • Nathan Goodyear on 12 May 18
     
    histamin augments NK activation with IL-2 therapy. Histamine blocks the monocyte/macrophate inhibition of IL-2 induced NK activity.
Nathan Goodyear

Immunotherapy with low-dose interleukin-2 in association with melatonin as salvage ther... - 0 views

www.spandidos-publications.com/...157

melatonin cancer IL-2 immunotherapy

shared by Nathan Goodyear on 10 May 18 - No Cached
  • Nathan Goodyear on 10 May 18
     
    Study, again of advanced cancer, with previous failed chemotherapy found that melatonin plus low-dose IL-2 therapy stimulated lymphocyte production and provided a partial response and stable disease.  No control group.
‹ Previous 21 - 40 of 234 Next › Last »
Showing 20▼ items per page